Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

European Journal of Pharmacology

Volumn 623, Issue 1-3, 2009, Pages 148-154

  Mu, James ^a   Petrov, Aleksandr ^a   Eiermann, George J ^a   Woods, John ^a   Zhou, Yun Ping ^a   Li, Zhihua ^a   Zycband, Emanuel ^a   Feng, Yue ^a   Zhu, Lan ^a   Roy, Ranabir Sinha ^a   Howard, Andrew D ^a   Li, Cai ^a   Thornberry, Nancy A ^a   Zhang, Bei B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cell mass; Dipeptidyl peptidase 4 (DPP 4); Sitagliptin; Type 2 diabetes

Indexed keywords

GLIPIZIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; SITAGLIPTIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREAS PERFUSION; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIETARY FATS; GLIPIZIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; KI-67 ANTIGEN; LIPIDS; LIVER; MALE; MICE; MICE, INBRED ICR; ORGAN SIZE; PYRAZINES; TRIAZOLES; TRIGLYCERIDES;

EID: 70350203952     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.09.027     Document Type: Article

References (38)

1. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A., Simpkins L.M., Taunk P., Huang Q., Han S.P., Abboa-Offei B., Cap M., Xin L., Tao L., Tozzo E., Welzel G.E., Egan D.M., Marcinkeviciene J., Chang S.Y., Biller S.A., Kirby M.S., Parker R.A., and Hamann L.G. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48 (2005) 5025-5037
2. Baggio L.L., and Drucker D.J. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review. Treat. Endocrinol. 1 (2002) 117-125
3. Bell G.I., and Polonsky K.S. Diabetes mellitus and genetically programmed defects in [beta]-cell function. Nature 414 (2001) 788-791
4. Brazg R., Xu L., Dalla Man C., Cobelli C., Thomas K., and Stein P.P. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes. Metab. 9 (2007) 186-193
5. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., Liu F., Woods J., Zycband E., Moller D.E., Thornberry N.A., and Zhang B.B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. PNAS 100 (2003) 6825-6830
6. Deacon C.F. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin. Investig. Drugs 16 (2007) 533-545
7. Deacon C.F., and Holst J.J. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochem. Biophys. Res. Commun. 294 (2002) 1-4
8. Drucker D. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs 12 (2003) 87-100
9. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
10. Drucker D., Easley C., and Kirkpatrick P. Sitagliptin. Nat. Rev. Drug Discov. 6 (2007) 109-110
11. Farilla L., Hui H., Bertolotto C., Kang E., Bulotta A., Di Mario U., and Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
12. Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., Navre M., Shi L., Skene R.J., Asakawa T., Takeuchi K., Xu R., Webb D.R., and Gwaltney II S.L. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 50 (2007) 2297-2300
13. Herman G.A., Stein P.P., Thornberry N.A., and Wagner J.A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin. Pharmacol. Ther. 81 (2007) 761-767
14. Holst J.J. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr. Med. Chem. 6 (1999) 1005-1017
15. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., Hickey G.J., Kowalchick J.E., Leiting B., Lyons K., Marsilio F., McCann M.E., Patel R.A., Petrov A., Scapin G., Patel S.B., Roy R.S., Wu J.K., Wyvratt M.J., Zhang B.B., Zhu L., Thornberry N.A., and Weber A.E. (2R)-4-oxo-4-[3-(trifluoromethyl)-5, 6-dihydro[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl]-1-(2, 4, 5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48 (2005) 141-151
16. Kim Y.B., Kopcho L.M., Kirby M.S., Hamann L.G., Weigelt C.A., Metzler W.J., and Marcinkeviciene J. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch. Biochem. Biophys. 445 (2006) 9-18
17. Kleppinger E.L., and Helms K. The role of vildagliptin in the management of type 2 diabetes mellitus. Ann. Pharmacother. 41 (2007) 824-832
18. Lacy P.E., and Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16 (1967) 35-39
19. Lauster C.D., McKaveney T.P., and Muench S.V. Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 64 (2007) 1265-1273
20. Luo J., Quan J., Tsai J., Hobensack C.K., Sullivan C., Hector R., and Reaven G.M. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 47 (1998) 663-668
21. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., and Turner R.C. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet. Med. 15 (1998) 297-303
22. Montana E., Bonner-Weir S., and Weir G.C. Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice. J. Clin. Invest. 91 (1993) 780-787
23. Mu J., Woods J., Zhou Y.-P., Roy R.S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A.D., Moller D.E., Thornberry N.A., and Zhang B.B. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
24. Otani K., Kulkarni R.N., Baldwin A.C., Krutzfeldt J., Ueki K., Stoffel M., Kahn C.R., and Polonsky K.S. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. Am. J. Physiol. Endocrinol. Metab. 286 (2004) E41-E49
25. Pick A., Clark J., Kubstrup C., Levisetti M., Pugh W., Bonner-Weir S., and Polonsky K. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47 (1998) 358-364
26. Porte D. Banting lecture, 1990. Beta-cells in type II diabetes mellitus. Diabetes 40 (1991) 166-180
27. Pospisilik J.A., Stafford S.G., Demuth H.-U., Brownsey R., Parkhouse W., Finegood D.T., McIntosh C.H.S., and Pederson R.A. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and {beta}-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51 (2002) 943-950
28. Pospisilik J.A., Martin J., Doty T., Ehses J.A., Pamir N., Lynn F.C., Piteau S., Demuth H.-U., McIntosh C.H.S., and Pederson R.A. Dipeptidyl peptidase IV inhibitor treatment stimulates {beta}-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 (2003) 741-750
29. Pratley R.E., and Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr. Med. Res. Opin. 23 (2007) 919-931
30. Stoffers D., Kieffer T., Hussain M., Drucker D., Bonner-Weir S., Habener J., and Egan J. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 (2000) 741-748
31. Sudre B., Broqua P., White R.B., Ashworth D., Evans D.M., Haigh R., Junien J.-L., and Aubert M.L. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 51 (2002) 1461-1469
32. Taylor S.I. Deconstructing type 2 diabetes. Cell 97 (1999) 9-12
33. Thornberry N.A., and Weber A.E. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem. 7 (2007) 557-568
34. Tourrel C., Bailbe D., Lacorne M., Meile M.-J., Kergoat M., and Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the {beta}-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51 (2002) 1443-1452
35. Trumper A., Trumper K., and Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J. Endocrinol. 174 (2002) 233-246
36. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 28 (2007) 187-218
37. Xu G., Stoffers D., Habener J., and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
38. Zhou Y.P., Cockburn B.N., Pugh W., and Polonsky K.S. Basal insulin hypersecretion in insulin-resistant Zucker diabetic and Zucker fatty rats: role of enhanced fuel metabolism. Metabolism 48 (1999) 857-864